04 August 2021 | Wednesday | News
BMG Pharma, a biopharmaceutical and B2B company headquartered in Milan with its chemical plant in Torviscosa (Italy), conducted a clinical study with encouraging results to assess the efficacy of BMG0705 Nasal Spray and BMG0703A Mouth Rinse in the treatment of asymptomatic COVID-19 patients.
These positive results could represent the starting point for the use of the products in the prevention as well as the early treatment of several infections such as SARS-CoV-2 and in the reduction of risk of infection and spread of virus. The efficiency of the tested products is based on the action of Hydrogen Peroxide combined to Hyaluronic Acid.
BMG0705 Nasal Spray is based on a patented nasal spray formulation, with the disinfecting action of Hydrogen Peroxide and Hyaluronic Acid creating a protective barrier: the barrier, adhering to the nasal mucosa, can stop COVID-19 and other infections and prevents them from worsening. In a similar way, BMG0703A Mouth Rinse forms a protective film which adheres to the oral mucosa preventing further irritations, acting against external agents and helps preventing complications caused by infections in the oral cavity such as seasonal flu and SarsCov-2.
The study enrolled a total of 106 people, who successfully completed an experimental protocol in the second quarter of 2021. The random allocation presented sufficient efficiency, as the associations between trial arm and covariates showed P values greater than 0.05. In the placebo arm, 57.6% of people had a positive PCR swab test following the index positive test, whereas in the active intervention arm that proportion was 31.9%, with a P value for the difference of 0.008. All subjects declared to have adhered to the study protocol and to have followed the prescription carefully (three full days of therapy) with no side effects.
The results from the analysis suggest that the active intervention under investigation can be effective in increasing the negativization rate of a positive PCR nose swab test for SARS-CoV-2. Further research is needed to confirm these results in some population subgroups.